ReNeuron stem cell trial clears first hurdle

An independent data safety monitoring board has signed off on the initial use of ReNeuron's stem cell therapy for stroke, clearing the way for more testing and fueling a jump in the company's share price. "We are delighted that the PISCES stroke clinical trial will now move forward to the next milestone, being the treatment of the remainder of the first patient cohort," said CEO Michael Hunt. "It is both encouraging and reassuring to hear that no safety issues have been observed with the first patient treated with ReN001 and again, we wish him and his family well." Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.